H. Alchalby

发表

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

N. Kröger, A. Zander, T. Binder, 2011, Leukemia.

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria

N. Kröger, A. Zander, F. Ayuk, 2015, Annals of Hematology.

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation

N. Kröger, A. Zander, F. Ayuk, 2014, Annals of Hematology.

JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms

N. Kröger, A. Heine, P. Brossart, 2015, British journal of haematology.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis

N. Kröger, G. Wulf, D. Wolf, 2014, Leukemia.

Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.

N. Kröger, H. Alchalby, 2014, Clinical lymphoma, myeloma & leukemia.

Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study

I. Apostolova, T. Derlin, N. Kröger, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.

N. Kröger, D. Atanackovic, A. Zander, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

M. Griesshammer, N. Kröger, T. Barbui, 2015, Leukemia.

Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT

N. Kröger, A. Zander, B. Fehse, 2010, Bone Marrow Transplantation.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.

Y. Hildebrandt, N. Kröger, A. Zander, 2009, Blood.

Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis

N. Kröger, A. Zander, E. Holler, 2012, British journal of haematology.

Impact of molecular residual disease post allografting in myelofibrosis patients

N. Kröger, B. Fehse, A. Zander, 2017, Bone Marrow Transplantation.

SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation

N. Kröger, U. Lehmann, H. Kreipe, 2014, Leukemia.

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

M. Heuser, F. Thol, A. Ganser, 2014, Leukemia.

Low frequency of calreticulin mutations in MDS patients

M. Heuser, F. Thol, A. Ganser, 2014, Leukemia.

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings

N. Kröger, M. Robin, J. Finke, 2013, Leukemia.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.

C. Bokemeyer, T. Stahl, N. Kröger, 2010, Experimental hematology.

Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis

N. Kröger, A. Zander, B. Fehse, 2010, Clinical and Experimental Medicine.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

N. Kröger, A. Zander, M. Binder, 2013, Annals of Hematology.

Reduced-Intensity Conditioning Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

N. Kröger, H. Alchalby, 2010, Current hematologic malignancy reports.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.

N. Kröger, P. Dreger, T. D. de Witte, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies.

N. Kröger, D. Blaise, C. Chabannon, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.

R. Porcher, N. Kröger, M. Robin, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation

N. Kröger, A. Zander, U. Pein, 2014, Bone Marrow Transplantation.

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis

N. Kröger, F. Ayuk, T. Zabelina, 2016, Bone Marrow Transplantation.

Donor choice according to age for allo-SCT for AML in complete remission

N. Kröger, A. Zander, F. Ayuk, 2013, Bone Marrow Transplantation.

Cytokine Expression Pattern in Bone Marrow Microenvironment after Allogeneic Stem Cell Transplantation in Primary Myelofibrosis.

N. Kröger, H. Kreipe, K. Hussein, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.

N. Kröger, H. Kreipe, J. Thiele, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.

M. Heuser, F. Thol, A. Ganser, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

M. Cazzola, H. Deeg, N. Kröger, 2015, Blood.

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis

T. Derlin, N. Kröger, F. Bengel, 2016, The Journal of Nuclear Medicine.

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Y. Hildebrandt, N. Kröger, A. Zander, 2010, Blood.

Ruxolitinib As Pretreatment Before Allogeneic Stem Cell Transplantation For Myelofibrosis

G. Wulf, D. Wolf, F. Ayuk, 2013 .

Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT

N. Kröger, A. Zander, U. Bacher, 2012, Bone Marrow Transplantation.

Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

N. Kröger, A. Zander, R. Brand, 2011 .